Lineage Cell Therapeutics (LCTX) revenue breakdown
By product, Collaboration Revenues is the largest at 93% of fiscal 2025 revenue, growing 87% a year over 4 years.
By region, UNITED STATES is the largest at 90% of fiscal 2021 revenue, growing 24% a year over 4 years.
Revenue by product
Fiscal years, as Lineage Cell Therapeutics reports them in its 10-K filings; fiscal 2025 total $15M.
| Products | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenues | — | — | — | — | $1M | $13M | $8M | $8M | $14M | 93% |
| Royalties, License and Other Revenues | $389,000 | $392,000 | $1M | $773,000 | $3M | $1M | $1M | $1M | $947,000 | 7% |
| Subscription and Advertisement Revenues | $1M | $691,000 | — | — | — | — | — | — | — | — |
| Grant Revenues | $2M | $4M | $2M | $1M | $445,000 | — | — | — | — | — |
| Sale of Research Products and Services | $8,000 | $333,000 | $257,000 | — | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Lineage Cell Therapeutics reports them in its 10-K filings; fiscal 2021 total $4M.
| Regions | 2017 | 2018 | 2019 | 2020 | 2021 | Share |
|---|---|---|---|---|---|---|
| UNITED STATES | $2M | $2M | $2M | $1M | $4M | 90% |
| Foreign | $2M | $3M | $1M | $666,000 | $446,000 | 10% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for LCTX.
Open LCTX in InvestinglyQuestions
Where does Lineage Cell Therapeutics make its money?
In fiscal 2025, by product: Collaboration Revenues $14M, Royalties, License and Other Revenues $947,000.
From Lineage Cell Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.